Biochimie 2014. doi: 10.1016/j.biochi.2013.12.023 34. Cifuentes-Rojas C, Shippen DE: Telomerase regulation. Mutat Res 2012, 730:20–27.PubMedCentralPubMedCrossRef 35. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK: Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.PubMedCentralPubMedCrossRef 36. Henson JD, Reddel

RR: Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010, 584:3800–3811.PubMedCrossRef 37. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN: High

level of telomerase RNA gene LCZ696 clinical trial expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2008, 98:1467–1474.PubMedCentralPubMedCrossRef 38. Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N: Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010, 10:254.PubMedCentralPubMedCrossRef 39. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson Erastin chemical structure BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR: A robust assay for alternative lengthening Resveratrol of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

Clin Cancer Res 2005, 11:217–225.PubMed 40. Johnson JE, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D: Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res 2007, 67:9221–9228.PubMedCrossRef 41. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK: Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004, 164:1523–1529.PubMedCentralPubMedCrossRef 42. Dei Tos AP: Liposarcomas: diagnostic pitfalls and new insights. Histopathology 2014, 64:38–52.PubMedCrossRef 43. Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002, 62:2993–2998.PubMed 44. Pilotti S, Della Torre G, Lavarino C, Sozzi G, VX-689 supplier Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA: Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13–22. J Pathol 1998, 185:188–190.PubMedCrossRef 45.